Francesco Cucco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Cucco has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Davide De Luca
Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy
2 shared publications Adam R. Coleman
School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
1 shared publication- Adrian Florentin Suman
Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy
1 shared publication - Andrew Davies
Cancer Sciences, University of Southampton, Southampton, UK
1 shared publication - Anna Schuh
Department of Oncology, University of Oxford, Oxford, UK
1 shared publication Cathy Burton
Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone as First-Line Therapy for Patients With Diffuse Large B-Cell Lymphoma
PURPOSE: Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The ACCEPT trial investigated the safety and efficacy of acalabrutinib in addition to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in first-line therapy. METHODS: In this phase Ib/II non-randomized study, eligible patients were treatment naïve, aged 16 years or older with a histologic diagnosis of DLBCL. The primary end point of the trial was to determine the recommended phase II dose (RP2D) of acalabrutinib in combination with R-CHOP and assess the safety and overall response rate (ORR). RESULTS: Between 2017 and 2020, 38 patients were enrolled. Of those enrolled, seven were ineligible. Median age was 64 years (range, 24-80); 76% were stage III/IV; 55% International Prognostic Index ≥3. No dose-limiting toxicities were observed, and the RP2D of acalabrutinib was 100 mg twice daily. The most common grade ≥3 adverse events at RP2D were neutropenia (37%), febrile neutropenia (13%), and diarrhea (10%). Eighty-eight percent of patients received six cycles of R-CHOP. Age did not compromise treatment delivery. At the RP2D, 20/24 (83%) patients had a complete response and three (12.5%) a partial response (ORR, 96% [95% CI, 79 to 100]). With median 30-months follow-up, the 24-month progression-free survival was 95% (95% CI, 68 to 99), event-free survival was 90% (95% CI, 66 to 97), and overall survival was 96% (95% CI, 73 to 99). CONCLUSION: The combination of acalabrutinib with R-CHOP is well tolerated, including in those older than 65 years. High efficacy in DLBCL was observed, regardless of cell-of-origin subtype. These findings support further investigation of this combination in a randomized trial.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Open AccessAcalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone as First-Line Therapy for Patients With Diffuse Large B-Cell Lymphoma
PURPOSE: Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The ACCEPT trial investigated the safety and efficacy of acalabrutinib in addition to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in first-line therapy. METHODS: In this phase Ib/II non-randomized study, eligible patients were treatment naïve, aged 16 years or older with a histologic diagnosis of DLBCL. The primary end point of the trial was to determine the recommended phase II dose (RP2D) of acalabrutinib in combination with R-CHOP and assess the safety and overall response rate (ORR). RESULTS: Between 2017 and 2020, 38 patients were enrolled. Of those enrolled, seven were ineligible. Median age was 64 years (range, 24-80); 76% were stage III/IV; 55% International Prognostic Index ≥3. No dose-limiting toxicities were observed, and the RP2D of acalabrutinib was 100 mg twice daily. The most common grade ≥3 adverse events at RP2D were neutropenia (37%), febrile neutropenia (13%), and diarrhea (10%). Eighty-eight percent of patients received six cycles of R-CHOP. Age did not compromise treatment delivery. At the RP2D, 20/24 (83%) patients had a complete response and three (12.5%) a partial response (ORR, 96% [95% CI, 79 to 100]). With median 30-months follow-up, the 24-month progression-free survival was 95% (95% CI, 68 to 99), event-free survival was 90% (95% CI, 66 to 97), and overall survival was 96% (95% CI, 73 to 99). CONCLUSION: The combination of acalabrutinib with R-CHOP is well tolerated, including in those older than 65 years. High efficacy in DLBCL was observed, regardless of cell-of-origin subtype. These findings support further investigation of this combination in a randomized trial.
- Open Access
- 20 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1346
MYC and Metabolomics: Can We Use What We Know for DLBCL Subtyping and Diagnosis?
Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5–15% of DLBCL cases harbor MYC gene translocations, often involving immunoglobulin genes as a translocation partner, and concomitant point mutations, correlating with a poor response to standard therapies. However, given the difficulty in detecting these abnormalities requiring specialized techniques and high-quality specimens, the use of metabolomics (i.e., the study of small metabolites in body fluids and tissues) can offer a useful alternative for the identification of high-risk DLBCL patients. Amino acids (AAs) are metabolites essential in the process of tumorigenesis and can increase immune escape and drug resistance. Therefore, we review the use of metabolomics to improve the diagnosis and prognosis in DLBCL patients in relation to the MYC role in the regulation of amino acid metabolism, as these metabolites may be used as potential biomarkers in a clinical environment.
- 20 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1346
Open AccessMYC and Metabolomics: Can We Use What We Know for DLBCL Subtyping and Diagnosis?
Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5–15% of DLBCL cases harbor MYC gene translocations, often involving immunoglobulin genes as a translocation partner, and concomitant point mutations, correlating with a poor response to standard therapies. However, given the difficulty in detecting these abnormalities requiring specialized techniques and high-quality specimens, the use of metabolomics (i.e., the study of small metabolites in body fluids and tissues) can offer a useful alternative for the identification of high-risk DLBCL patients. Amino acids (AAs) are metabolites essential in the process of tumorigenesis and can increase immune escape and drug resistance. Therefore, we review the use of metabolomics to improve the diagnosis and prognosis in DLBCL patients in relation to the MYC role in the regulation of amino acid metabolism, as these metabolites may be used as potential biomarkers in a clinical environment.
- Open Access
- 24 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4010-4017
MYC Point Mutations in Cancer: A Reboot and a Sequel
The impact of MYC point mutations on cancer development and progression is poorly explored, particularly if compared with other MYC genetic alterations, such as translocations and amplifications. MYC point mutations were first observed more than 40 years ago in lymphoid malignancies, and some of these were functionally characterized. In the following decades, only a few studies on MYC point mutations were reported until recently when analyses of the myriad cancer-related high-throughput sequencing studies brought new life to this research topic and expanded the range of malignancies involved. However, to date, all this information can be retrieved only by consulting the specific literature or navigating publicly available databases, and a proper collection and systematic description of these genetic changes are urgently needed. In this review, we run through the steps of the MYC point mutations line of research with a comprehensive illustration of the recurrent variants occurring in the MYC coding, noncoding, and regulatory regions in cancer. With this work, we also aim to highlight the current gaps in knowledge to stimulate research in this field, which could ultimately result in the realization of its translational potential.
- 24 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4010-4017
Open AccessMYC Point Mutations in Cancer: A Reboot and a Sequel
The impact of MYC point mutations on cancer development and progression is poorly explored, particularly if compared with other MYC genetic alterations, such as translocations and amplifications. MYC point mutations were first observed more than 40 years ago in lymphoid malignancies, and some of these were functionally characterized. In the following decades, only a few studies on MYC point mutations were reported until recently when analyses of the myriad cancer-related high-throughput sequencing studies brought new life to this research topic and expanded the range of malignancies involved. However, to date, all this information can be retrieved only by consulting the specific literature or navigating publicly available databases, and a proper collection and systematic description of these genetic changes are urgently needed. In this review, we run through the steps of the MYC point mutations line of research with a comprehensive illustration of the recurrent variants occurring in the MYC coding, noncoding, and regulatory regions in cancer. With this work, we also aim to highlight the current gaps in knowledge to stimulate research in this field, which could ultimately result in the realization of its translational potential.